OncoTraj Benchmark
Explore score history ↗OncoTraj is a public benchmark for predicting acquired resistance to first-line osimertinib in EGFR-mutant non-small-cell lung cancer. It provides a harmonized dataset of 813 patients from three real-world sources, with locked splits, an evaluation harness, and six baselines, defining three tasks: 12-month progression classification, time-to-progression regression, and resistance mechanism classification.
- Released
- 2026-06-09
- Evaluates
- Biology & Drug Discovery, Language & Knowledge, cs.LG
- Openness
- unknown
- Importer
- Claire Radar
- Review status
- unreviewed
OncoTraj paper, code and dataset
No reported scores are on record for this benchmark yet.